BeiGene
BGNE
#984
Rank
NZ$34.83 B
Marketcap
$312.42
Share price
1.55%
Change (1 day)
6.33%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - P/B ratio

P/B ratio as of December 2024 : 5.81

According to BeiGene 's latest financial reports the company has a price-to-book ratio of 6.02001.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

BeiGene - P/B ratio (from 2016 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-315.986.81%
2023-12-315.604.67%
2022-12-315.3519.41%
2021-12-314.48-27.83%
2020-12-316.21-40.94%
2019-12-3110.5121.26%
2018-12-314.75-26.93%
2017-12-316.5090.55%
2016-12-313.41
2015-12-31N/A
2014-12-31N/A

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
3.48-40.19%๐Ÿ‡บ๐Ÿ‡ธ USA
0.7718-86.72%๐Ÿ‡บ๐Ÿ‡ธ USA